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Acute-on-chronic liver failure (ACLF) carries high short-term mortality. The North American Consortium for the Study of End-
Stage Liver Disease (NACSELD)–ACLF score, positive if ≥2 organ failures are present, is a bedside tool that predicts short-term 
mortality in patients with cirrhosis. However, it was created using major liver referral centers, where a minority of patients with cir-
rhosis are hospitalized. Therefore, this study used the Nationwide Inpatient Sample, a nationally representative database, from 2005 
to 2014 to externally validate the NACSELD-ACLF score in a cohort of patients with decompensated cirrhosis who were identified 
by a validated algorithm. Organ failures were identified using diagnosis codes. The primary objective was to evaluate the associa-
tion between the NACSELD-ACLF score and inpatient mortality, whereas secondary objectives compared outcomes depending 
on presence of infection or hospitalization at a transplant center. Multivariate logistic regression was used to compare outcomes, 
and area under the curve was calculated. There were 1,523,478 discharges that were included with 106,634 (7.0%) having a positive 
NACSELD-ACLF score. Patients were a mean 58 years old, and a majority were white men. Infection was present in 33.7% of the 
sample. Inpatient survival decreased with each organ failure and if infection was present. Patients with the NACSELD-ACLF score 
had significantly lower inpatient survival on crude (94% versus 48%; P < 0.001) and multivariate analysis (odds ratio [OR], 0.08; 
95% confidence interval [CI], 0.07-0.08) and area under the receiver operating characteristic curve 0.77 (95% CI, 0.77-0.78). Liver 
transplant centers had clinically similar but significantly better survival at each organ failure, in patients with the NACSELD-ACLF 
score, and on multivariate analysis (OR, 1.17; 95% CI, 1.13-1.22). Using a national cohort, our study validated the NACSELD-
ACLF score as an excellent, simple bedside tool to predict short-term survival in patients with decompensated cirrhosis.
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SEE Editorial ON PAGE 179Acute-on-chronic liver 
failure (ACLF) is a highly prevalent condition among 
hospitalized patients with decompensated cirrhosis 
and is associated with high morbidity and mortality. 
Definitions of ACLF vary across different societ-
ies with European and North American consortiums 
generally requiring at least the presence of cirrhosis, 
whereas the Asian definition includes patients with-
out cirrhosis but with chronic liver disease in addition 
to those with compensated cirrhosis.(1,2) Nonetheless, 
ACLF is widely considered to be present when a 
severe acute decompensation occurs in the setting of 
chronic liver disease, leading to multiorgan failure.(1,3) 
On the basis of this definition, studies estimate ACLF 
rOsenblatt et al.
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to be present in 30% of hospitalized patients with 
decompensated cirrhosis and is associated with a 34% 
1-month mortality.(4) Because of the high prevalence 
and short-term mortality, accurately prognosticating 
patients with ACLF is imperative.
Prior literature has investigated the use of scoring sys-
tems derived from prospective cohorts to prognosticate 
ACLF patients. First, the Chronic Liver Failure Acute-
on-Chronic Liver Failure in Cirrhosis (CANONIC) 
group in Europe evaluated 1343 patients and established 
3 prognostic stages of ACLF based on the presence of 
organ failures, defined by the Chronic Liver Failure–
Sequential Organ Failure Assessment score.(4) The North 
American Consortium for the Study of End-Stage Liver 
Disease (NACSELD), a consortium of liver referral 
centers from the United States and Canada, also iden-
tified the presence and number of organ failures as the 
key driver of mortality in hospitalized patients with cir-
rhosis and, thus, further refined the predictive model.(5) 
More recently, the NACSELD centers reported that the 
presence of at least 2 organ failures (such as shock, grade 
3 or 4 encephalopathy, renal failure requiring hemodi-
alysis, or respiratory failure requiring mechanical venti-
lation) accurately predicted 30-day survival, which was 
defined as the NACSELD-ACLF score.(6) This easily 
calculated bedside score theoretically enhances clinical 
decision making, but the generalizability of using the 
score is unknown.
The NACSELD cohort was derived from patients 
with cirrhosis from large liver transplantation (LT) 
referral centers, and therefore, the applicability of the 
NACSELD-ACLF score to the general population 
remains unclear. The inclusion of only LT referral cen-
ters could lead to potential bias by identifying only the 
sickest patients, or conversely, better LT candidates who 
are less frail with fewer comorbidities. When assessing 
the hospitalization patterns of patients with cirrhosis 
on a national scale, the majority are not hospitalized at 
a teaching or major metropolitan hospital,(7) and may 
not necessarily be represented within the NACSELD 
cohort. Therefore, this study aimed to evaluate perfor-
mance and externally validate the NACSELD-ACLF 
score among hospitalized patients with decompensated 
cirrhosis throughout the United States using a large, 
nationally representative database.
Patients and Methods
Data sOUrce anD participant 
selectiOn
This study used the Nationwide Inpatient Sample 
(NIS; called National Inpatient Sample from 2012 
to 2014) from the Healthcare Cost and Utilization 
Project (HCUP), Agency for Healthcare Research and 
Quality, from 2005 to 2014.(8) The NIS is a large, na-
tionally representative database of hospital discharges 
for all payers. The sampling methodology of the NIS 
changed in 2012 from a sample of 20% of hospitals 
participating in HCUP to a 20% sample of discharges 
from all participating hospitals. NIS data include de-
mographic information, discharge disposition, diag-
noses, procedures, length of stay, hospital charges, and 
inpatient mortality. The discharges are weighted to 
provide nationally representative estimates.
All discharges of patients aged 18-99 years old with 
both a diagnosis of cirrhosis (defined by International 
Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] codes 571.2, 571.5, and 
571.6) and the presence of a decompensating event 
(defined by ICD-9-CM code of bleeding esophageal 
varices [456.0, 456.21], spontaneous bacterial peritoni-
tis [567.23 along with the code for paracentesis 54.91], 
ascites [789.5, 789.59], and hepatic encephalopathy 
[HE; 572.2]) were included in the study. This identi-
fication algorithm was modified from a previously vali-
dated algorithm.(9) Our selection of a cohort of patients 
with decompensated cirrhosis was specifically chosen to 
be similar to those who were eligible for the definition 
of ACLF under the NACSELD cohort.(2) Exclusion 
criteria were similar to that of the NACSELD studies: 
LT, liver transplantation; MELD, Model for End-Stage Liver 
Disease; MELD-Na, Model for End-Stage Liver Disease–sodium; 
NACSELD, North American Consortium for the Study of End-Stage 
Liver Disease; NIS, Nationwide Inpatient Sample; OR, odds ratio.
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a history of prior LT, human immunodeficiency virus 
(HIV), actively pregnant, or extrahepatic malignancy 
(Supporting Materials).(5) Additionally, patients were 
excluded if they underwent LT within 1 day of admis-
sion because their hospitalization would be primarily 
for LT and not for a complication of cirrhosis.
OUtcOMes anD eXpOsUres
Similar to the NACSELD study,(6) organ failure was 
defined by the presence of shock, grade 3 or 4 en-
cephalopathy, renal failure requiring hemodialysis, or 
respiratory failure requiring mechanical ventilation. 
Previously used algorithms were used to identify organ 
failures. Shock was identified by the presence of an 
ICD-9-CM code for septic shock (785.52), circulatory 
shock (785.59), or vasopressor use (00.17).(10) HE was 
diagnosed by the ICD-9-CM code (572.2), though 
unlike in the NACSELD cohort, the grade and se-
verity could not be determined using this database. 
Renal failure requiring hemodialysis was diagnosed by 
the presence of both acute kidney injury (ICD-9-CM 
codes 584.5, 584.6, 584.7, 584.8, and 584.9) and he-
modialysis (ICD-9-CM codes 39.95, V45.11,V56.0, 
and V56.1).(11) Respiratory failure requiring mechan-
ical ventilation was defined as the ICD-9-CM code 
for invasive mechanical ventilation (ICD-9-CM codes 
96.04, 96.70, and 96.72) or tracheostomy placement 
(ICD-9-CM codes 31.1, 31.2, 31.21, and 31.29). 
Patients with infection were, on the basis of previous 
studies,(7,12) identified as having a diagnosis of either 
pneumonia, urinary tract infection, Clostridium diff i-
cile infection, spontaneous bacterial peritonitis, sepsis, 
bacteremia, or cholangitis (Supporting Materials).
ObJectives
The primary objective of the study was to evaluate the 
association of the NACSELD-ACLF score and inpa-
tient survival. Secondary objectives included evaluating 
the impact of infection and the impact of hospital type, 
defined as LT or non-LT centers. LT centers were de-
termined based on the whether an LT was performed 
at the hospital over the study period.
statistical analYsis
STATA, version 14.0 (StataCorp, College Station, 
TX) was used to analyze the data. Continuous vari-
ables were expressed as means with interquartile ranges 
and analyzed by the adjusted Wald test. Categorical 
variables were expressed as percentages and analyzed 
by chi-square test. Multivariable logistic regression was 
performed to analyze outcomes. Because the NIS does 
not provide laboratory or vital sign information, the 
same model used by the NACSELD (including age, 
Model for End-Stage Liver Disease [MELD] score, 
white blood cell count, albumin, and the presence of 
infection)(6) could not be used, and thus, a unique mul-
tivariable logistic regression model was constructed. 
The model controlled for covariates that were selected 
a priori and were known to impact survival in patients 
with cirrhosis, including age, sex, presence of infection, 
presence of ascites, gastrointestinal (GI) bleeding, and 
the Elixhauser comorbidity index.(13) Interaction terms 
were included if found to be significant. Standard er-
rors were clustered by center to limit the impact of 
potential outliers. The area under the receiver oper-
ating characteristic curve (AUROC) was calculated 
for the models. This study was deemed exempt by the 
Institutional Review Board at Weill Cornell Medicine.
Results
patient DeMOgrapHics
Of the 1,612,930 discharges of patients with decom-
pensated cirrhosis identified, 1,523,478 were included 
in the study with 106,634 (7.0%) meeting the thresh-
old for the NACSLD-ACLF score (positive when 
there were 2 or more organ failures; Fig. 1). The prev-
alence of the NACSELD-ACLF score increased from 
2005 to 2014 (5.7%-8.6%; Supporting Table 1). Men 
and patients with alcohol-related liver disease were sig-
nificantly more likely to have the NACSELD-ACLF 
score (Supporting Table 2).
The mean age was 58 years, 36.4% of patients were 
women, and the majority of patients were white (65.8%; 
Table 1). Most patients were from the lowest socioeco-
nomic quartile, measured by median household income 
in the patient’s ZIP code (31.9%). Most patients were 
admitted in densely populated areas, and 246,124 (16.2%) 
patients were hospitalized at a LT center. Alcohol-related 
liver disease was the most common etiology of liver dis-
ease and was significantly more common in patients with 
NACSELD-ACLF score. Alcoholic hepatitis, although 
unreliably diagnosed using ICD-9-CM codes,(14) was 
present in 6.9% of the sample, and those patients had 
an increased prevalence of the NACSELD-ACLF 
score (9.9% versus 6.7%). Ascites (92.5%) was the most 
common sign of decompensation. There were 516,089 
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(33.7%) patients who were infected during their hospi-
talization. The most common infection was a urinary 
tract infection 190,792 (12.4%) followed by pneumonia 
(7.0%), spontaneous bacterial peritonitis (5.2%), celluli-
tis and soft tissue infection (5.2%), C. difficile infection 
(2.3%), and cholangitis (0.7%). Of the patients with 
infection, 11.9% had sepsis or septicemia. Of patients 
with an infection, 38.4% had at least 2 infections.
crUDe sUrvival
Overall, 1,386,365 (91%) patients survived their hospital-
ization during the study. Patients with the NACSELD-
ACLF score had significantly lower survival (48% versus 
94%; P < 0.001; Fig. 2A). Survival in patients with the 
NACSELD-ACLF score significantly improved from 
2005 to 2014 (38%-53%; Supporting Table 1). Survival 
was also inversely correlated with the number of organ 
failures, starting at 97% survival for those without organ 
failure and decreasing to 25% for those with 4 organ fail-
ures (Fig. 2B). At each level of organ failure, infected pa-
tients had significantly worse inpatient survival. Patients 
with multiple infections had higher rates of multiple 
organ failures (32% versus 5%; P  <  0.001) and worse 
overall survival (68% versus 93%; P < 0.001) than those 
with a single infection.
When evaluating survival rates of specific organ 
failures, patients with infection had higher prevalence 
and worse survival for each specific organ failure (Fig. 
2C). Overall, HE was the most common (26.6% prev-
alence) organ failure but also had the highest associ-
ated survival (86.0%). Of the individual organ faliures, 
shock and respiratory failure had the lowest inpatient 
survival (48.3% and 47.1%, respectively).
regressiOn analYsis
Univariate logistic regression demonstrated that an in-
creasing number of organ failures was associated with 
decreased odds of inpatient survival (Table 2). Once at 
least 2 organ failures, or the NACSELD-ACLF score, 
was present, the combination of organ failures did not 
substantially change survival (Supporting Table 3). In 
the multivariate analysis controlling for age, sex, the in-
teraction of GI bleeding and presence of ascites, presence 
of infection, and the Elixhauser comorbidity index, the 
NACSELD-ACLF score was significantly associated 
with a marked reduction in inpatient survival (adjusted 
odds ratio [OR], 0.08; 95% confidence interval [CI], 
0.07-0.08; P  <  0.001; Table 3). In this multivariate 
model, the presence of infection (adjusted OR, 0.42; 
95% CI, 0.41-0.43; P <  0.001) and the interaction of 
Fig. 1. Inclusion and exclusion of the study cohort.
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GI bleeding and ascites (adjusted OR, 0.78; 95% CI, 
0.73-0.84; P < 0.001) were both significantly associated 
with reduced inpatient survival. The AUROC for the 
NACSELD was 0.77 (95% CI, 0.77-0.78).
lt center
Of the 246,124 patients hospitalized at a LT center, 
7654 (3.1%) underwent LT during their hospitalization. 
Patients who were hospitalized at an LT center were more 
likely to have at least 1 organ failure (66% versus 62%; 
P < 0.001) but were less likely to have the NACSELD-
ACLF score (6% versus 10%; P  <  0.001). Survival at 
each number of organ failure (Fig. 3A) was significantly 
higher in LT centers compared with non-LT centers 
(P < 0.001). This remained true even when excluding 
any patient who underwent an LT. Survival from respi-
ratory failure was significantly higher in LT centers (48% 
versus 47%; P  <  0.001), whereas survival from shock 
(50% versus 44%; P  <  0.001) and renal failure (63% 
table 1. Demographic characteristics of the sample comparing patients Who Meet the nacselD-aclF score With 




No NACSELD-ACLF  
(n = 1,416,844, 93.0%)
Age, years 58 ± 0.02 56 ± 0.08 58 ± 0.02
Sex, female 554,546 (36.4) 43,826 (41.1) 510,720 (33.8)
Race
White 1,002,449 (65.8) 67,500 (63.3) 934,949 (66.0)
Black 152,348 (10.0) 9,237 (9.6) 142,611 (10.1)
Hispanic 269,656 (17.7) 18,727 (18.5) 250,729 (17.7)
Asian 31,993 (2.1) 2,566 (2.5) 29,427 (2.1)
Other 67,032 (4.4) 7,904 (7.4) 59,128 (4.2)
Median household income by ZIP code quartile
First 485,989 (31.9) 32,050 (30.1) 453,939 (32.0)
Second 400,675 (26.3) 26,888 (25.2) 373,787 (26.4)
Third 358,017 (23.5) 25,501 (23.9) 332,516 (23.1)
Fourth 278,797 (18.3) 22,195 (20.8) 256,602 (18.1)
Hospital location*
Metropolitan city center, >1 million 527,123 (34.6) 39,948 (37.5) 487,175 (34.4)
Metropolitan county (not center), >1 million 344,306 (22.6) 24,612 (23.1) 319,694 (22.6)
County population, 250,000-999,999 292,508 (19.2) 19,494 (18.3) 273,014 (19.3)
County population, 50,000-249,999 129,496 (8.5) 8,307 (7.8) 121,189 (8.6)
Micropolitan county 143,207 (9.4) 8,841 (8.3) 134,366 (9.5)
Other 86,838 (5.7) 5,432 (5.1) 81,406 (5.7)
LT hospital 246,124 (16.2) 25,379 (23.8) 220,745 (15.6)
Infection 516,089 (33.7) 75,710 (71.0) 440,379 (30.9)
Upper GI bleed 278,796 (18.3) 37,109 (34.8) 241,687 (17.1)
Esophageal variceal bleed 132,543 (8.7) 18,448 (17.3) 114,095 (8.1)
Ascites 1,409,217 (92.5) 89,999 (84.4) 1,319,218 (93.1)
Type of cirrhosis
Hepatitis C 457,043 (30.0) 20,900 (19.6) 436,143 (30.8)
Alcohol-related 856,195 (56.2) 70,805 (66.4) 785,390 (55.5)
Length of stay, days 7.0 ± 0.01 14.5 ± 0.10 6.5 ± 0.01
Total charge, US $ 54,920 ± 172 176,070 ± 1525 45,933 ± 130
Inpatient survival 1,386,365 (91.0) 50,971 (47.8) 1,335,394 (94.2)
NOTE: Data are given as mean ± standard deviation or n (%).
*Only variable that was not significant (P < 0.05). Only the two most common etiologies of cirrhosis are listed. Hepatitis C and Alcohol-
related are not mutually exclusive.
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versus 59%; P < 0.001) was higher in non-LT centers 
(Fig. 3B). On multivariate analysis, controlling for age, 
sex, the interaction of GI bleeding and presence of as-
cites, presence of infection, the Elixhauser comorbidity 
index, and NACSELD-ACLF score, hospitalization at 
an LT center was associated with increased survival (ad-
justed OR, 1.17; 95% CI, 1.13-1.22; P < 0.001; Table 4).
Discussion
The purpose of this study was to use a nationally repre-
sentative database to externally validate the performance 
of NACSELD-ACLF score in predicting inpatient 
survival. We identified 1.5 million hospitalized patients 
with decompensated cirrhosis over 10  years and con-
firmed that organ failures were indeed a major driver of 
mortality in this population across the United States, 
particularly when the patient was infected. Furthermore, 
by selecting a population where the majority were hos-
pitalized at non-LT centers, this analysis also validates 
the use of NACSELD-ACLF score among patients who 
may not have the option for LT.
The use of a database with national sampling in 
order to validate the NACSELD-ACLF score is cru-
cial because the majority of patients in the United 
States are seen at nontransplant centers. Despite only 
one-sixth of the hospitalized population with cirrhosis 
being seen at academic LT centers, LT centers gen-
erate the vast majority of the literature advising inpa-
tient cirrhosis management. Similar to this study, an 
analysis of the Veterans Administration database over 
a similar timeframe consisted of <10% of patients 
hospitalized at LT centers, but this population was 
Fig. 2. Inpatient survival stratified by NACSELD-ACLF score, 
number of organ failures, and type of organ failure. (A) Inpatient 
survival by the presence of the NACSELD-ACLF score stratified 
by the presence of infection. (B) Inpatient survival by the number of 
organ failures stratified by the presence of infection. (C) Inpatient 
survival by the type of organ failure stratified by the presence of 
infection.
table 2. Univariable logistic regression survival 





Unadjusted OR 95% CI Unadjusted OR 95% CI
No organ failure Reference Reference
1 organ failure 0.26 0.25-0.27 0.26 0.25-0.27
2 organ failures 0.05 0.05-0.05 0.04 0.04-0.05
3 organ failures 0.02 0.02-0.03 0.02 0.02-0.03
4 organ failures 0.02 0.01-0.02 0.02 0.02-0.03
table 3. Multivariable logistic regression survival 
probability for nacselD-aclF score in the entire cohort
Variable Adjusted OR 95% CI P Value
NACSELD-ACLF score 0.08 0.07-0.08 <0.001
Age 0.98 0.98-0.99 <0.001
Female 1.20 1.16-1.23 <0.001
Interaction of GI bleeding and 
ascites
0.78 0.73-0.84 <0.001
Infection 0.42 0.41-0.43 <0.001
Elixhauser comorbidity index 0.990 0.979-0.996 0.004
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predominantly composed of male veterans, limiting its 
external validation.(15) The NACSELD-ACLF score 
demonstrates its broadest appeal among patients and 
providers at non-LT hospitals. Patients seen in these 
hospitals do not have access to prompt salvage LT, 
and the presence of the NACSELD-ACLF score can 
quickly stratify these patients into a low (<50%) and 
high (>90%) chance of survival. These stark differences 
warrant a consideration of changing the goals of care 
when the NACSELD-ACLF score is present. Given 
the underuse of palliative care services in patients with 
liver disease who are denied LT,(16) early identification 
of these patients would allow for a smoother transition 
to palliative care. For example, other diseases, most 
notably metastatic non–small cell lung cancer, have 
demonstrated not only improved quality of life and 
mood but also longer survival in patients who received 
early palliative care and avoided aggressive care.(17) At 
the same time, patients who are potential transplant 
candidates, who meet the criteria of the NACSELD-
ACLF score, and who are at a nontransplant hospital 
require urgent transfer to a transplant-capable hospital. 
The presence of the NACSELD-ACLF score can be 
used as an early indicator to initiate a timely transfer 
in a non-LT hospital or, similarly, warrant a rapid LT 
evaluation for a patient already in an LT hospital.
Although there were minor differences between 
the results of our analysis and the initial NACSELD-
ACLF article(6) overall, the findings of both stud-
ies are quite similar. Survival for all organ failures 
was poor in both cohorts, but our cohort had nota-
bly reduced survival among patients with shock and 
especially with respiratory failure. Interestingly, 
we observed a significantly worse survival (10% 
higher mortality) among patients with NACSELD-
ACLF compared with the NACSELD study group 
cohort.(6) Although there are no clear explanations 
for this discrepancy, it is likely driven by patients 
who are not LT candidates or a lack of inpatient liver 
services that are typical at major liver referral cen-
ters. Unsurprisingly, despite utilization of a different 
multivariate regression model, our study also found 
that NACSELD-ACLF was associated with a more 
potent effect on survival (OR, 0.08 versus 0.16). 
When comparing the impact of the NACSELD-
ACLF score in the original and validation study, 
it showed itself in the original NACSELD-ACLF 
study to be simpler and more strongly linked with 
inpatient survival when compared with the MELD 
score (OR, 0.95). Notably, our analysis was also in 
agreement with O’Leary et al.(6) in that infection 
was associated with significantly worse outcomes. 
This finding is in contrast to the CANONIC study, 
in which there were similar mortality rates among 
patients with and without infection.(4) However, it 
Fig. 3. Inpatient survival stratified by hospitalization at an LT 
center. (A) Inpatient survival by the number of organ failures 
depending on hospitalization in an LT center. (B) Inpatient 
survival by the type of organ failure depending on hospitalization 
in an LT center.
table 4. Multivariable logistic regression survival 
probability for nacselD-aclF score in the entire cohort 
With inclusion of Hospitalization at a lt center
Variable Adjusted OR 95% CI P Value
Hospitalization at a LT center 1.17 1.13-1.22 <0.001
NACSELD-ACLF Score 0.08 0.07-0.08 <0.001
Age 0.98 0.98-0.99 <0.001
Female 1.20 1.16-1.23 <0.001
Interaction of GI bleeding and 
ascites
0.79 0.73-0.84 <0.001
Infection 0.42 0.41-0.43 <0.001
Elixhauser comorbidity index 0.990 0.981-0.998 0.02
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is worth noting that infection was associated with 
ACLF, which, in the CANONIC study, was associ-
ated with poor outcomes.
The limitations of this study are inherent to the 
use of large databases in general, which is prone to 
administrative coding errors. Despite this limita-
tion, the power of using 1.5  million hospitaliza-
tions is profound and is a tradeoff of administrative 
databases. The NIS specifically lacks laboratory 
data, which is crucial in determining liver disease 
severity, such as the calculation of Model for End-
Stage Liver Disease–sodium (MELD-Na) or Child-
Turcotte-Pugh score. Furthermore, a key element 
within the NACSELD-ACLF multivariate model is 
white blood cell count, which was appreciated as an 
important marker of both inflammation and prog-
nosis.(6) Nonetheless, the model used in this study, 
although lacking laboratory covariates, included 
factors known to increase mortality in patients with 
cirrhosis. Because only 1 ICD-9-CM code was used 
to diagnose HE, we were unable to differentiate 
between stages of HE severity. The inclusion of HE 
at all stages in our study likely explains why survival 
in our study is higher for patients with HE compared 
with the study by O’Leary et al.(6) Unfortunately, 
because of poor coding algorithms, acute insults, 
such as alcoholic hepatitis and acute viral hepatitis, 
are challenging to diagnose and study individually 
when using a large database.(14) Additionally, because 
this study is retrospective, it can merely confirm the 
findings demonstrated by the NACSELD-ACLF 
through association and is not, by itself, predictive of 
inpatient survival. Although the weaknesses of large 
databases are well documented, the external validity 
of this study is substantial given its broad representa-
tion of LT and non-LT hospitals in various locations 
in the country as compared with well-recognized 
liver referral hospitals included in the NACSELD 
study group. It is also worth noting that ACLF is 
a clinical syndrome that results in organ failures, in 
which laboratory values would be helpful but not 
fully necessary to diagnose.
Still, this analysis brings to light an increas-
ingly important question: Does the NACSELD-
ACLF score prior to LT impact post-LT survival? 
Unfortunately, although our database is limited in 
its ability to analyze the relationship between the 
timing of organ failures and LT, a recent analysis 
of the United Network for Organ Sharing data-
base noted that despite the number of organ failures 
being associated with a worse posttransplant mor-
tality, the absolute difference between those with no 
organ failures (90% 1-year survival) and those with 
5-6 organ failures (81% 1-year survival) prior to LT, 
was only 9%.(18) Similar to the MELD-Na score, the 
NACSELD-ACLF score is excellent in predicting 
short-term mortality, but organ failures themselves 
do not necessarily indicate a poor posttransplant 
prognosis. In fact, patients meeting criteria for 
ACLF on the LT waiting list had higher mortality 
than those with acute liver failure, which was previ-
ously thought to confer the highest short-term mor-
tality for patients with liver disease.(19) In contrast 
to non-LT centers, LT centers should be incentiv-
ized to continue to consider patients with multiple 
organ failures for LT, especially when patients derive 
significant short-term and longterm survival benefit 
from LT.(20) Prospective data from the NACSELD 
cohort demonstrate higher rates of pre-LT mortality 
in those with ACLF but no difference in post-LT 
survival among listed patients.(21)
However, retrospective studies have demonstrated 
mixed results. A study of patients with ACLF grade 
3 from France had outcomes after LT similar to that 
of lower-grade ACLF, whereas other studies from 
France(22) and Germany(23) show ACLF to be a potent 
risk factor for post-LT mortality. Currently, it is diffi-
cult to confidently predict post-LT mortality in patients 
who are entering LT with ACLF. Persistent renal fail-
ure after LT, which is a known adverse outcome after 
LT that is connected to mortality, may be a potential 
explanation for poor outcomes after LT in the setting 
of ACLF.(24) Frailty, which is a major driver of wait-list 
mortality,(25) is likely to be related to post-LT mortality 
as well. Future investigation is warranted because our 
study was limited by difficulties in interpreting timing 
of diagnoses and organ failures in relation to LT.
Given the rapid deterioration of patients with 
ACLF, prediction of poor prognosis early in the time 
course is crucial. Our study now further supports the 
broad application of the NACSELD-ACLF score to 
identify patients hospitalized with ACLF, regardless 
of hospital type, and offers an easy bedside tool that 
patients, caregivers, and their providers can use to bet-
ter recognize poor outcomes and enhance either early 
recognition of LT candidacy or, conversely, futile care 
in those without LT. In patients without access to LT 
who are very likely to die before discharge, the pres-
ence of the NACSELD-ACLF score predicted dismal 
survival; although on the contrary, a lack of 2 or more 
liver transplantatiOn, vol. 26, no. 2, 2020 rOsenblatt et al.
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organ failures was associated with a >94% inpatient 
survival. These findings represent a call to action for 
non-LT hospitals, who can use this simple bedside 
test to determine disposition in patients, depending on 
their transplant candidacy, to provide better quality care 
and outcomes.
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